newsfilter
← Latest News
GlobeNewswire·

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies